Tuesday, September 11, 2007
Isentress (Raltegravir) Pricing
We know that Pfizer's Selzentry (maraviroc) costs $10,585 per year (see Pharmalot's posting here). Any thoughts on what Merck's new integrase inhibitor Isentress will be priced at? Given that it doesn't have any kind of tropism test issues, perhaps Merck will price it higher than Selzentry. Further looks like Isentress does not have some of the safety issues Selzentry has (though the incidence of cancer in the trials was slightly higher). Will be interesting to see if Merck prices it like Roche's Fuzeon (20K per year) or whether they match Selzentry or end up somewhere in between. Pharmalyst welcomes reader comments on this.